Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$26.33 USD
+0.83 (3.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $26.36 +0.03 (0.11%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth B Momentum A VGM
Pacira (PCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$46.30 | $57.00 | $36.00 | 81.57% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Pacira comes to $46.30. The forecasts range from a low of $36.00 to a high of $57.00. The average price target represents an increase of 81.57% from the last closing price of $25.50.
Analyst Price Targets (10)
Broker Rating
Pacira currently has an average brokerage recommendation (ABR) of 1.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.30 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 70% and 30% of all recommendations. A month ago, Strong Buy made up 70%, while Buy represented 30%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.30 | 1.30 | 1.30 | 1.30 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/4/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
3/1/2024 | Truist Securities | Leszek Sulewski | Strong Buy | Strong Buy |
3/1/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
2/8/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
12/20/2023 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
11/4/2023 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.30 |
ABR (Last week) | 1.30 |
# of Recs in ABR | 10 |
Average Target Price | $46.30 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | 0.65 |